Attorney General Gentner Drummond has announced settlements with Heritage Pharmaceuticals and Apotex, totaling $49.1 million, attributing to their involvement in price-fixing conspiracies for generic prescription drugs. In a move to offer redress, Oklahomans who purchased these drugs between Jan. 1, 2010, and Dec. 31, 2018, may qualify for compensation, as per details released by the Oklahoma Office of the Attorney General. This legal stride forms part of the ongoing multistate litigations targeting the broader issue of artificially inflated drug prices.
In addition to the financial settlements, Heritage and Apotex have pledged to aid in the prosecutorial efforts against several other implicated corporations and executives. The agreement with Heritage, amounting to $10 million, is awaiting preliminary approval in the U.S. District Court for the District of Connecticut in Hartford. Apotex's settlement, a heftier sum of $39.1 million, hinges on the lawful formalities, including obtaining necessary endorsements from all involved states and territories. Drummond commended this progress, saying, "This is a positive development in our fight to hold accountable drug manufacturers for artificially manipulating prices, reducing competition and unreasonably restraining trade for numerous generic prescription drugs," according to the official announcement.
The settlements are seminal to the efforts of a coalition, comprising nearly all states and territories, which is preparing for a seminal trial in Connecticut. Thus far, three antitrust complaints have been filed, exposing different clusters of drugs, companies, and executives involved in alleged collusion. Investigations tying these cases together have relied on evidence from cooperating witnesses, an exhaustive database of documents, and meticulous examination of telephone records.
The alleged collusion was camouflaged in innocuous activities such as industry dinners and casual get-togethers. During such occasions, industry players employed codewords and socially charged phrases to perpetuate an anti-competitive culture. The cases paint a picture of an industry where terms like "fair share," "playing nice in the sandbox" and "responsible competitor" were euphemisms for price-fixing and market manipulation. Among the substantial evidentiary records is a cooperator's notebook, which chronicled conversations and meetings, revealing the minutiae of the infringement tactics, as detailed by the Oklahoma Office of the Attorney General.
